CLDX Celldex Therapeutics, Inc.
FY2025 10-K
Celldex Therapeutics, Inc. (CLDX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 25, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Development of therapeutic antibodies targeting mast cell biology for severe inflammatory and autoimmune diseases
- • New emphasis on bispecific antibody platform, highlighted by CDX-622 targeting TSLP and SCF with Phase 1 studies initiated in 2024-2026
Management Discussion & Analysis
- • No revenue or YoY change disclosed; focus on clinical R&D for barzolvolimab and CDX-622
- • R&D expenses $245.1M in 2025 vs $163.6M in 2024 and $118.0M in 2023, driven by barzolvolimab program ($198.3M in 2025)
Risk Factors
- • FDA regulatory delays from recent 43-day government shutdown Oct-Nov 2025 impacting review timelines
- • Global supply chain disruptions threatening clinical trial material supplies and contract manufacturing capacity
Financial SummaryXBRL
Revenue
$2M
Net Income
-$259M
Operating Margin
-18599.8%
Net Margin
-16748.0%
ROE
-49.1%
Total Assets
$583M
EPS (Diluted)
$-3.90
Operating Cash Flow
-$211M
Source: XBRL data from Celldex Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Celldex Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.